ORIGINAL INVESTIGATION. Age-Related Response to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection
|
|
- Diane Lee
- 6 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Age-Related to Interferon Alfa Treatment in Women vs Men With Chronic Hepatitis C Virus Infection Jun Hayashi, MD, PhD; Yasuhiro Kishihara, MD; Kumiko Ueno, MD; Kouzaburo Yamaji, MD; Yasunobu Kawakami, MD; Norihiro Furusyo, MD; Yasunori Sawayama, MD; Seizaburo Kashiwagi, MD, PhD Background: Interferon alfa is used widely for patients with chronic hepatitis C virus (HCV) infection. Little is known, however, of the relationship between patients sex and the effectiveness of interferon alfa treatment in these patients. Methods: We treated 311 patients (199 men and 112 women) with human lymphoblastoid interferon (6 million units subcutaneously every day for 2 weeks and 3 times a week for 22 weeks) and observed them for an additional 6 months. Serum HCV RNA levels and genotype were tested by polymerase chain reaction before treatment. A liver biopsy was also done. For the purposes of this study, a complete response was defined as the elimination of HCV RNA for at least 6 months after the termination of treatment. Results: The rate of complete response was 27.1% for men and 24.1% for women. With multiple logistic regression analysis, the HCV RNA level (P.001), genotype (P.001), patients sex (P.05), and the interaction between sex and age were associated with a complete response to interferon alfa. The rate of complete response was 33.3% in men aged 39 years and younger, 25.0% in men aged 40 years and older, 75.0% in women aged 39 years and younger, and 15.6% in women aged 40 years and older. The odds ratio by group was 1.00, 0.72, 4.38, and 0.21, respectively. Conclusions: Our finding that women aged 39 years and younger are responsive to interferon alfa treatment suggests that hormonal activity, in particular the level of estrogen, may be associated with the sustained elimination of HCV. Arch Intern Med. 1998;158: From the Department of General Medicine, Kyushu University Hospital, Fukuoka, Japan. PATIENTS WITH chronic hepatitis C virus (HCV) infection should receive careful treatment because they are at a high risk of developing hepatocellular carcinoma. 1,2 Interferon alfa (IFN- ) reduces serum aminotransferase levels, improves histological activity, 3,4 and eliminates HCV RNA in patients with chronic HCV infection, 5,6 and its use is associated with a decreased incidence of hepatocellular carcinoma. 7 It was previously reported that factors associated with the HCV infection itself are more important than patient characteristics for effective IFN- treatment of patients with chronic HCV infection, 6 and that the HCV RNA level and genotype were useful predictors of a complete response, results that were supported by other investigators. 6,8-10 Little is known, however, of the relationship between patients sex and the effectiveness of IFN- treatment in patients with chronic HCV infection. The rate of response to IFN- treatment by sex has been calculated in small-scale studies that found no significant differences between the sexes. 8,10,11 It has conversely been shown that HCV appeared to be eliminated more commonly in women than in men, as men with antibodies to HCV tested positive for HCV RNA significantly more frequently than women. Similarly, among patients with HCV RNA, liver biochemical test results were less frequently abnormal in women than in men. 12 In this study, we examined the relationship between the outcome of IFN- treatment in 311 patients with chronic HCV infection categorized by sex and age who were treated with a 6-month course of natural IFN- to clarify whether or not sex and age are predictive markers for the effectiveness of IFN- treatment. RESULTS Of 311 patients treated with natural IFN-, 81 (26.0%) had a complete response, 123 (39.5%) had a partial response, and 107 (34.4%) had no response. Of 199 men,
2 PATIENTS AND METHODS PATIENTS We studied 311 Japanese patients (199 men and 112 women) with chronic HCV infection who were treated with IFN- at Kyushu University Hospital, Fukuoka, Japan, from April 1, 1992, to March 31, Of these 311, 102 (32.8%) had a history of blood transfusion, but none had a history of alcohol or drug abuse or homosexuality. None of the women had estrogen replacement treatment. All patients had the antibody to HCV by the second-generation assay and did not have the hepatitis B surface antigen or the antibody to the human immunodeficiency virus. Before treatment, a liver biopsy was done for all patients. In all patients during the 6-month period, HCV RNA was detected before treatment. The HCV RNA of genotype 1b was found in 224 (72.0%), genotype 2a in 58 (18.6%), and genotype 2b in 29 (9.3%). The HCV RNA levels of serum RNA (logarithmic transformed copy numbers per 50 µl of serum) ranged from 2 to 7 copies per 50 µl. METHODS Paired blood specimens were obtained every 2 weeks during the treatment, every 4 weeks for at least 3 months before entry, and 6 months after the cessation of treatment. All serum specimens were separated and stored at 20 C until tested for antibody to HCV, HCV RNA, HCV RNA genotype, and HCV RNA levels. Antibodies to HCV (HCV EIA II, Abbott Laboratories, North Chicago, Ill) 13 were examined using enzyme-linked immunosorbent assay. Assays for hepatitis B surface antigen and human immunodeficiency virus antibody were done using commercial serological tests. TREATMENT REGIMEN The patients were given subcutaneous injections of natural IFN- (human lymphoblastoid interferon, Sumyferon, Sumitomo Co, Tokyo, Japan). A dose of 6 million units was given daily for the first 2 weeks, then 3 times a week for the next 22 weeks. The total dose given was 480 million units during a 24-week period. This schedule of IFN- treatment is currently in wide use in Japan. Fully informed written consent was obtained from each patient, and the trials were approved by the Ethics Committee of Kyushu University Hospital. DEFINITION OF RESPONSE TO IFN- In this study, a complete response was defined as negative results on HCV RNA tests by the end of the scheduled treatment and sustained negativity beyond 6 months; partial response as negative results on HCV RNA tests by the end of the scheduled treatment, but the virus reappeared during the 6-month follow-up; and no response when HCV RNA was not eliminated at any time during the observation period. HCV RNA BY POLYMERASE CHAIN REACTION Ribonucleic acid was extracted from 50 µl of serum by Sepa Gene RV (Sanko Junyaku, Tokyo, Japan), and complementary DNA was synthesized using random primers and reverse transcriptase (Super Script II; GIBCO BRL, Gaithersburg, Md). The HCV RNA was detected by 2-stage polymerase chain reaction (PCR) using primers from the 5 -noncoding region of the HCV genome, as previously described. 14 GENOTYPE OF HCV RNA The HCV RNA genotype was determined by 2-stage PCR using universal and type-specific primers from the putative C gene of the HCV genome with a modification of the method of Okamoto et al 15 and Hayashi et al. 16 The genotype nomenclature was based on the system proposed by Simmonds et al. 17 HCV RNA LEVEL BY COMPETITIVE PCR The level of HCV RNA was determined by means of competitive PCR using a modification of the methods of Hayashi et al 16 and Kato et al. 18 By recombinant PCR, we obtained mutant HCV RNA with the EcoRI site in the 5 noncoding region. This mutant HCV complementary DNA fragment was cloned into the pgem-4z vector, which is a cloning and transcription vector (Promega Corp, Madison, Wis). In vitro RNA transcription from PvuII-digested pgem-4z was done using T7RNA polymerase (Riboprobe Gemini System II; Promega Corp) according to the manufacturer s instructions. Primers and a probe were constructed for the 5 -noncoding region. The amplified products were analyzed by electrophoresis after the digestion of mutant HCV RNA by EcoRI, mutant HCV RNA being demonstrated at 106 and 112 base pairs and HCV RNA from patients at 218 base pairs. The size of the PCR product for each patient was compared with that of the diluted mutant HCV RNA. STATISTICAL ANALYSIS Statistical analysis was performed using a commercially available software package (BMDP Statistical Software Inc, Los Angeles, Calif) for the IBM 3090 system computer. 19 The BMDP 4F program (ie, 2-way and multiway frequency tables, measures of association, and the log-linear model)was used for the 2 test with the Bonferroni correction for multiple comparison. The BMDP program LR was used for the stepwise logistic regression analysis, which was done to evaluate the relationship between the clinical features and the proportion of patients with chronic HCV infection responding completely to IFN- treatment. All categorical clinical features (ie, sex [male=0, female=1], age [ 39 years=0, 40 years=1], serum alanine aminotransferase level [ 99 IU/L=0, 100 IU/L=1], histological features [chronic persistent hepatitis=0, chronic active hepatitis=1, severe chronic active hepatitis=2, and cirrhosis=3], and HCV RNA genotype [1b=0, 2a=1, 2b=2]), were handled as dichotomous variables. Using this method, the most significant associated variable was entered into the model. After adjusting for that variable, the next most significant variable was added to the model. This procedure was continued until no more variables met the entry criteria. A P value of.05 or less was considered statistically significant. 178
3 (27.1%) had a complete response, 68 (34.2%) had a partial response, and 77 (38.7%) had no response; of 112 women, 27 (24.1%) had a complete response, 55 (49.1%) had a partial response, and 30 (26.8%) had no response. The frequency of a partial response was significantly higher in women than in men (P.01), but the frequencies of a complete response and no response did not differ between the sexes (Table 1). To clarify the effectiveness of IFN- treatment, properties of HCV and patient characteristics were compared based on sex (Table 2). No significant difference was found in the number of patients having a complete response by sex, based on pretreatment levels of alanine aminotransferase and histological features of the liver. Those who had a complete response included 37 (16.5%) of 224 patients with genotype 1b, 33 (56.9%) of 58 with genotype 2a, and 11 (37.9%) of 29 with genotype 2b. Significant differences were noted in the number of complete responses between genotypes 1b and 2a (P.001) and between 1b and 2b (P.01). No significant differences were noted in the number of patients with a complete response by sex and genotype. The frequency of a complete response was significantly higher in patients with HCV RNA levels of less than 4 by competitive PCR (65.1%) than in those with levels greater than 5 (16.1%) (P.001). Of 144 patients with HCV RNA levels above Table 1. Outcome of Interferon Alfa Treatment by Sex Sex Complete No. (%) of With Partial No Men (27.1) 68 (34.2)* 77 (38.7) Women (24.1) 55 (49.1)* 30 (26.8) Total (26.0) 123 (39.5) 107 (34.4) *Men vs women, P.01. 6, only 6.9% had a complete response. No significant difference was found, however, in the number of patients with a complete response by sex and HCV RNA level. To search for predictive factors that would influence the response to IFN- treatment, we used multiple logistic regression analysis. The HCV RNA level (P.001), genotype (P.001), sex (P=.05), and interaction between sex and age were associated with a complete response to natural IFN-. As the HCV RNA level decreased, there was a tendency for the probability of a complete response to increase. For patients with genotypes 2a and 2b, there was an increased probability of having a complete response. Moreover, a significant correlation was found when women were grouped by age (Table 3). In the men, the rate of complete response ranged from 20.0% to 47.4% for those younger than 60 years and decreased to 10.6% in those aged 60 years and older. A complete response in women ranged from 71.4% to 80.0% in those aged 39 years and younger, 25.0% in the 40- to 44-years age group, 16.7% to 18.2% in the 45- to 59- years age group, and 8.6% in those aged 60 years and older (Figure). The rate of complete response was significantly higher in women (80%) than in men (20%) in the 35- to 39-year-old group (P.05), but there were no sex differences in other age groups. The rate of response to IFN- treatment was remarkably decreased in women 40 years of age and older, but it did not decrease with aging in the men. The outcome of IFN- treatment for these 311 patients based on sex and age is shown in Table 4. were separated into 4 groups by sex and age: group 1 consisted of men younger than 40 years; group 2, men older than 40 years; group 3, women younger than 40 years; and group 4, women older than 40 years. The rate of complete response in each group was 33.3%, 25.0%, 75.0%, and 15.6%, respectively, significantly higher in group 3 than in groups 1 (P.01), 2 (P.001), and 4 Table 2. Clinical Features of With Chronic Hepatitis C Virus (HCV) Infection Clinical Feature Men (n=199) Women (n=112) Total (N=311) Complete Complete Complete Alanine aminotransferase level 99 IU/L (26.3) (22.4) (24.8) 100 IU/L (29.0) 27 8 (29.6) (29.2) Histological* CPH 24 7 (29.2) 20 6 (30.0) (29.5) CAH (28.1) (32.6) (29.5) Severe CAH (29.7) 26 5 (19.2) (26.7) LC 22 3 (13.6) 23 2 (8.7) 45 5 (11.1) Genotype 1b (18.2) (13.2) (16.5) 2a (63.3) (50.0) (56.9) 2b 21 8 (38.1) 8 3 (37.5) (37.9) HCV-RNA level (10 n copies/50 µl) (68.6) (60.7) (65.1) (18.3) (11.9) (16.1) *CPH indicates chronic persistent hepatitis; CAH, chronic active hepatitis; and LC, liver cirrhosis. Genotypes 1b vs 2a, P.001. Genotypes 1b vs 2b, P.01. HCV RNA level 4vs 5, P
4 Complete, % Table 3. Factors Contributing to Complete to Interferon-Alfa Treatment in With Chronic Hepatitis C Virus (HCV) Infection: Results of a Stepwise Logistic Regression Analysis Factors Coefficient SE Odds Ratio* P HCV RNA level HCV RNA genotype (reference to 1b) 2a b Sex Age Sex-age interaction *The odds ratio was defined as the ratio of the odds for a complete response to the odds for an incomplete (partial) response Age, y The rates of complete response to interferon alfa treatment in patients with chronic hepatitis C virus infection, based on sex and age. Closed circles indicate men; open circles, women; and asterisks, P.05 when comparing women vs men. (P.001) and higher in group 1 than in group 4 (P.05). The odds ratio of group 3 was 4 times that of group 1, 6 times that of group 2, and 20 times that of group 4. COMMENT Table 4. The Odds Ratio of a Complete to Interferon-Alfa Treatment in With Chronic Hepatitis C Virus Infection by Sex and Age Category, Sex and Age Complete P Odds Ratio Men 40 y (33.3) Men 40 y (25.0) 0.72 Women 40 y (75.0) Women 40 y (15.6) 0.21 Total (26.0)... In the present study of the effectiveness of IFN- treatment for patients with chronic HCV infection, focused on patient s sex, we obtained evidence that age was associated with response to the treatment in women, but not in men. Although there was no significant malefemale difference in the overall rate of complete response to IFN- treatment, being a younger woman ( 40 years) was a favorable marker for successful treatment. This study also confirmed that the HCV RNA genotype and the HCV RNA level are important factors of response to IFN- treatment. 6,8-10 To exclude bias, the relation between the outcome of treatment and patients sex was investigated, based on these HCV markers. Histological features are also useful predictive markers. In this study, the response rate was low in patients with advanced liver disease, especially in women. This is consistent with the results of multiple logistic regression analysis showing that older women had a low response because most patients with advanced liver disease were 40 years of age and older. The duration of hepatitis was not correlated with the response to IFN- treatment in a previous study, 6 but the relationship is difficult to determine because the onset of hepatitis is uncertain in many cases. Therefore, we excluded it and other factors such as a history of blood transfusion, antibody to c100 (which is the first-generation assay for antibody to HCV), and antibody to GOR (which is isolated from the plasma of a chimpanzee infected with a human non-a, non-b hepatitis agent) that did not correlate with the response to IFN- treatment. 6 In contrast to previous studies in which only the biochemical response was assessed, this study defined a complete response as a sustained return to normal serum aminotransferase levels and the disappearance of HCV RNA by PCR. Because serum aminotransferase levels return to normal in some patients, either during treatment or within 6 months, those with a complete response in the previous studies may have had HCV RNA in the serum and thus were at risk of the reactivation of chronic hepatitis C. 20 Therefore, we defined a complete response as the elimination of HCV RNA from the serum that was sustained for 6 months after the cessation of IFN- treatment. This study indicates that HCV RNA is more easily eliminated from younger women than older women. The relationship between the response to IFN- treatment and aging is controversial. Other investigators reported that older age was not an unfavorable marker for IFN- treatment, 21,22 whereas Garson et al 23 reported that patients who had a complete response were significantly younger than those who had no response. Moreover, Horiike et al 22 reported that elderly patients with a low level of HCV RNA respond well to IFN- treatment. Their studies were done on a small series, and they defined a response to IFN- treatment as the return of aminotransferase levels to normal after the cessation of treatment, with no attention given to the status of HCV RNA. We obtained clear findings that an older age ( 40 years) was one of the unfavorable markers of the elimination of HCV RNA from the serum of patients with chronic HCV infection. Of interest was the finding that the response to IFN- treatment was better in women than in men among patients younger than 40 years and that the response decreased remarkably in women aged 40 years and older. Why HCV appears to act differently in younger and older women, however, is unclear. During perimenopause (from age 40 years), ovulation can be erratic, and plasma go- 180
5 nadotropin levels frequently reach menopausal level, even when plasma estrogen levels are within the menstrual range. 24,25 These data suggest that the decreased rate of a complete response to IFN- treatment may correspond with decreases in estrogen levels. Interleukin 1, associated with an inflammatory response, is stimulated by low concentrations of estrogen and progesterone. A low concentration of estrogen allows peripheral blood monocytes to secrete more interleukin The spontaneous production of interleukin 1 by peripheral mononuclear cells has been shown to be significantly higher in patients with chronic hepatitis C than in healthy control subjects, then decreased in those with a complete response after the administration of IFN-. 27 This cytokine production may alter the effectiveness of IFN- treatment in perimenopausal and menopausal women with chronic HCV infection. Because women do have a response to IFN- treatment, as shown in Table 1, and in this study HCV RNA was eliminated during treatment more often in women than in men, hormonal activity, in particular the level of estrogen, may be associated with the sustained elimination of HCV in patients undergoing IFN- treatment for HCV infection. Hormone levels should be measured before treatment. A pertinent subject for investigation would be the results of a combination of estrogen replacement therapy 28 and IFN- therapy for older women. Accepted for publication May 29, Reprints: Jun Hayashi, MD, PhD, Department of General Medicine, Kyushu University Hospital, Higashi-Ku, Fukuoka , Japan. REFERENCES 1. Bruix J, Barrera JM, Calbet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;2: Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2: Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multi-center randomized, controlled trial. N Engl J Med. 1989;321: Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321: Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-. Hepatology. 1992; 15: Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89: Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon- on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346: Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon- therapy: relationship to genotypes of hepatitis C virus. Hepatology. 1992;16: Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993;341: Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon 2a therapy. J Med Virol. 1995;46: Tsubota A, Chayama K, Arase Y, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol. 1993;8: Hayashi J, Kishihara Y, Yamaji K, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol. 1995;90: Hayashi J, Nakashima K, Kishihara Y, et al. Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-a, non-b liver disease. J Infect. 1993;26: Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cdna clone derived from a blood borne non-a, non-b viral hepatitis genome. Science. 1989;244: Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Med Virol. 1992;73: Hayashi J, Yoshimura E, Kishihara Y, et al. Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol. 1996;91: Simmonds P, Alberti A, Bonino F, et al. A proposed system for the nomenclature for genotypes of hepatitis C virus. Hepatology. 1994;19: Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantitation of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993;18: Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP Statistical Software Manual. Berkeley: University of California Press; Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Ann Intern Med. 1996;124: Bresci G, Corso LD, Romanelli AM, Giuliano G, Pentimore F. The use of recombinant interferon alfa-2b in elderly patients with anti-hcv-positive chronic active hepatitis. J Am Geriatr Soc. 1993;41: Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol. 1995;10: Garson JA, Brillanti S, Whitby M, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol. 1995;45: Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab. 1987;65: MacNaughton J, Banah M, McCloud P, Hee J, Burger H. Age-related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol. 1992;36: Polan ML, Daniele A, Kuo A. Gonadal steroids modulate human monocyte interleukin-1 (IL-1) activity. Fertil Steril. 1988;49: Kishihara Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K, Kashiwagi S. IL-1 and TNF- produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 1996;41: Salamone LM, Pressman AR, Seeley DG, Cauley JA. Estrogen replacement therapy: a survey of older women s attitudes. Arch Intern Med. 1996;156:
Evaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C
Evaluation of Interferon Treatment in Cirrhotic Patients with Hepatitis C Tatsuya IDE, Michio SATA, Hiroshi SUZUKI, Shiroh MURASHIMA, Ichiroh MIYAJIMA, Miki SHIRACHI and Kyuichi TANIKAWA The Second Department
More informationPapers. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA
J Clin Pathol 1999;52:807 811 807 Papers Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical College Hospital, No 100, Shih-Chuan 1st Rd, Kaohsiung, Taiwan, Republic of China M-L
More informationL\\\\\\1 V\\ High dose interferon treatment in chronic hepatitis C. Group A. Group B. Dosage. Treatment period
SI 14 Gut 1993; supplement: SI 14-S118 Institute of Medical Science, School ofmedicine, St Marianna University, Japan S Iino Correspondence to: Dr S Iino, Institute of Medical Science, School of Medicine,
More informationDETECTION OF HEPATITIS C VIRUS cdna SEQUENCE BY THE POLYMERASE CHAIN REACTION IN HEPATOCELLULAR CARCINOMA TISSUES
Jpn. J. Med. Sci. Biol., 43, 89-94, 1990. Short Communication DETECTION OF HEPATITIS C VIRUS cdna SEQUENCE BY THE POLYMERASE CHAIN REACTION IN HEPATOCELLULAR CARCINOMA TISSUES Tetsuo YONEYAMA, Kenji TAKEUCHI,
More informationHCV HIV +*+ Human immunodeficiency virus HIV hepatitis C virus HCV HIV HCV HCV HIV HIV
,**- The Japanese Society for AIDS Research The Journal of AIDS Research +0 HIV HCV + + + + + + + + +, +, :HCV HIV HAART / : +*+ +*0,**- Human immunodeficiency virus HIV hepatitis C virus HCV HIV,* HCV
More informationComparison of Quantitative HCV RNA Assays in Chronic Hepatitis C
MICROBIOLOGY AND INFECTIOUS DISEASE Original Article Comparison of Quantitative HCV RNA Assays in Chronic Hepatitis C SHERAJ JACOB, MD, DEBORAH BAUDY, ELIZABETH JONES, LIZHE XU, PhD, ANDREW MASON, MBBS,
More informationSEE EDITORIAL ON PAGE 436 PATIENTS AND METHODS
Interferon Beta Prevents Recurrence of Hepatocellular Carcinoma After Complete Resection or Ablation of the Primary Tumor A Prospective Randomized Study of Hepatitis C Virus Related Liver Cancer KENJI
More informationQuantitation of hepatitis C viral RNA in liver
82 8 Clin Pathol 1995;48:82-825 Faculty of Medicine, Kobe University, Kobe, Japan: 2nd Department of Internal Medicine M Sugano S Yoon M Kasuga 1st Department of Pathology Y Hayashi T Ninomiya K Ohta H
More informationLymphoblastoid interferon alfa treatment in
152 Department of Paediatrics, University of Naples 'Federico II', Italy R Iorio P Pensati S Porzio I Fariello S Guida A Vegnente Correspondence and reprint requests to: Dr Raffaele Iorio, Dipartimento
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationChanges in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy
MAJOR ARTICLE Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy Hidenori Toyoda, 1 Takashi Kumada, 1 Seiki
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationKENJI IKEDA, 1 SATOSHI SAITOH, 1 YASUJI ARASE, 1 KAZUAKI CHAYAMA, 1 YOSHIYUKI SUZUKI, 1 MASAHIRO KOBAYASHI, 1 AKIHITO TSUBOTA, 1
Effect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis Type C: A Long-Term Observation Study of 1,643 Patients Using Statistical Bias Correction With Proportional
More informationBacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection
ORIGINAL ARTICLE Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection Akira Kawano 1, Eiichi Ogawa 2, Norihiro Furusyo 2, Makoto Nakamuta 3, Eiji
More informationA Pilot Study of Corticosteroid Priming for Lymphoblastoid Interferon Alfa in Patients With Chronic Hepatitis C
A Pilot Study of Corticosteroid Priming for Lymphoblastoid Interferon Alfa in Patients With Chronic Hepatitis C KAZUAKI CHAYAMA, AKIHITO TSUBOTA, MASAHIRO KOBAYASHI, MICHIE HASHIMOTO, YUKIKO MIYANO, HIROMI
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE CORRELATION BETWEEN SERUM AMINOTRANFERASE LEVELS AND HCV RNA LOAD IN HEPATITIS C VIRUS RELATED CHRONIC LIVER DISEASE. SINGH J 1, CHHINA
More informationAntiviral Therapy 11: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2
Antiviral Therapy 11:985 994 A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre
More informationEditorial. Hepatitis C: From Laboratory to Bedside
Editorial Hepatitis C: From Laboratory to Bedside It has been 15 years since Feinstone and coworkers' at the National Institutes of Health described a type of hepatitis occurring in recipients of blood
More informationPolymerase Chain Reaction RNA Assays To Establish
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1992, p. 2145-2149 0095-1137/92/082145-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 30, No. 8 Use of Aminotransferase, Hepatitis C Antibody,
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHepatitis C: A Hepatologist s Approach to an Infectious Disease
CLINICAL PRACTICE Ellie J. C. Goldstein, Section Editor INVITED ARTICLE Hepatitis C: A Hepatologist s Approach to an Infectious Disease Peter M. Rosenberg Department of Medicine, St. John s Health Center,
More informationEIJI TANAKA, 1 CHIHARU OHUE, 2 KATSUMI AOYAGI, 2 KENJIRO YAMAGUCHI, 2 SHINTARO YAGI, 2 KENDO KIYOSAWA, 1,3 AND HARVEY J. ALTER 4
Evaluation of a New Enzyme Immunoassay for Hepatitis C Virus (HCV) Core Antigen With Clinical Sensitivity Approximating That of Genomic Amplification of HCV RNA EIJI TANAKA, 1 CHIHARU OHUE, 2 KATSUMI AOYAGI,
More informationYun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang
The Korean Journal of Hepatology 2012;18:41-47 http://dx.doi.org/10.3350/kjhep.2012.18.1.41 pissn: 1738-222X eissn: 2093-8047 Original Article Rapid normalization of alanine aminotransferase predicts viral
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationRelative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection
PO Box 2345, Beijing 123, China World J Gastroenterol 25;11(43):6848-6852 www.wjgnet.com World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com E L S E V I E R 25 The WJG Press and Elsevier Inc.
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationResearch Article Clinical Features of Adult Patients with Acute Hepatitis B Virus Infection Progressing to Chronic Infection
International Hepatology, Article ID 358206, 5 pages http://dx.doi.org/10.1155/2014/358206 Research Article Clinical Features of Adult Patients with Acute Hepatitis B Virus Infection Progressing to Chronic
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationThe Natural Course of Chronic Hepatitis C: A Comparison Between Patients With Genotypes 1 and 2 Hepatitis C Viruses
The Natural Course of Chronic Hepatitis C: A Comparison Between Patients With Genotypes 1 and 2 Hepatitis C Viruses MASANORI KOBAYASHI, EIJI TANAKA, TAKESHI SODEYAMA, AKIHIKO URUSHIHARA, AKIHIRO MATSUMOTO,
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More information: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,
5 Vol. 34, pp. 5 23, 2006 C IFN 0 2 : 8 4 20 63 986 990 C 993 S7 C A F2 IFN IFNa2a 9MIU 24W HCV-RNA 995 2 F HCV-RNA IFN 0 2004 5 S8 20 mm CT SPIO-MRI 6 TP6.3 g dl, Alb4.3 g dl, GOT7 IU l, GPT26 IU l, g-gtp40
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationA "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist
A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist Information regarding pathogenesis and appropriate management of chronic hepatitis C continues to evolve.
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationRibavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon
408 Journal of Hepatology, 1993; 19:408-412 1993 Elsevier Scientific Publishers Ireland Ltd, All rights reserved. 0168-8278/93/$06.00 HEPAT 01452 Ribavirin in the treatment of chronic hepatitis C unresponsive
More informationIL10 rs polymorphism is associated with liver cirrhosis and chronic hepatitis B
IL10 rs1800896 polymorphism is associated with liver cirrhosis and chronic hepatitis B L.N. Cao 1, S.L. Cheng 2 and W. Liu 3 1 Kidney Disease Department of Internal Medicine, Xianyang Central Hospital,
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationDuring the course of chronic hepatitis B virus. Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B
Long-Term Outcome After Spontaneous HBeAg Seroconversion in Patients With Chronic Hepatitis B Yao-Shih Hsu, 1 Rong-Nan Chien, 1 Chau-Ting Yeh, 1 I-Shyan Sheen, 1 Hung-Yi Chiou, 2 Chia-Ming Chu, 1 and Yun-Fan
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationSerum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features
856 Department of Clinical and Experimental Medicine, University of Padova, Italy L De Moliner P Pontisso G L De Salvo L Cavalletto L Chemello A Alberti Correspondence to: Dr P Pontisso, Clinica Medica
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationEFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS
ORIGINAL ARTICLE EFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS Rukhsana Javed Farooqi, Javed Iqbal Farooqi Department
More informationTRANSFUSION-ASSOCIATED HEPATITIS G VIRUS INFECTION AND ITS RELATION TO LIVER DISEASE
TRANSFUSION-ASSOCIATED HEPATITIS G VIRUS INFECTION AND ITS RELATION TO LIVER DISEASE THE INCIDENCE OF TRANSFUSION-ASSOCIATED HEPATITIS G VIRUS INFECTION AND ITS RELATION TO LIVER DISEASE HARVEY J. ALTER,
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationA Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis B
C linical S tudy Janardan Singh* Anupam Chakraborty* Mukul Chandra Dhar* Sudhakaran C** Mitra SK** A Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis
More informationHEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM
HEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM Event Name: Event Time Period: ACUTE Clinical Presentation (CDC 2012): CDC Event (2012): HEPB Lifelong immunity An acute illness with a discrete
More informationShort communication Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients
Antiviral Therapy 1; 15:1179 1183 (doi: 1.3851/IMP18) Short communication Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients Akito Nozaki
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS
IJCRR Section: Healthcare Sci. Journal Impact Factor 4.016 Research Article HEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS Amit H. Agravat 1, Mital J. Gamit 2, Gauravi
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationSATHEESH NAIR AND ROBERT P.PERRILLO
Serum Alanine Aminotransferase Flares During Interferon Treatment of Chronic Hepatitis B: Is Sustained Clearance of HBV DNA Dependent on Levels of Pretreatment Viremia? SATHEESH NAIR AND ROBERT P.PERRILLO
More informationSTEVE NISHIMURA FALL 1990 HEPATITIS C. Introduction
STEVE NISHIMURA FALL 1990 HEPATITIS C Introduction With the recent identification and sequencing of the viral genome of the hepatitis C virus (HCV) and the subsequent development of an ELISA assay, a wealth
More informationMusarrat Iqbal, Ali Zohair Nomani, Muhammad Saleem Qureshi, Saba Binte Kashmir, Marina Wazir and Kamran Rasheed,
World Journal of Medical Sciences 8 (2): 130-134, 2013 ISSN 1817-3055 IDOSI Publications, 2013 DOI: 10.582/idosi.wjms.2013.8.2.7344 Treatment Induced Decline in Hematological Cell Lines as a Predictor
More informationClinical guidelines on the management of hepatitis C
Gut 2001;49(Suppl I):i1 i21 i1 Department of Gastroenterology, Royal Berkshire Hospital, London Road, Reading RG5 5AN, UK J C L Booth Institute of Liver Studies, King s College London, Bessemer Road, London
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationEvaluation of a Novel Serotyping System for Hepatitis C Virus: Strong Correlation with Standard Genotyping Methodologies
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1995, p. 2978 2983 Vol. 33, No. 11 0095-1137/95/$04.00 0 Copyright 1995, American Society for Microbiology Evaluation of a Novel Serotyping System for Hepatitis C
More informationCommunity Acquired and Post-Transfusion Hepatitis C Is There a Difference?
Community Acquired and Post-Transfusion Hepatitis C Is There a Difference? Pages with reference to book, From 9 To 11 A. R. Qureshi, S. Hamid, W. Jafri, H. Shah, Z. Abbas, S. Abid, H. Khan ( Departments
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationEffects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
Yamasaki et al. BMC Gastroenterology 212, 12:139 RESEARCH ARTICLE Open Access Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients Kazumi Yamasaki 1,6*, Mayumi Tomohiro 2, Yumiko
More informationIncreased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin
Anatomic Pathology / INCREASED HEPATIC IRON DEPOSITION ASSOCIATED WITH RIBAVIRIN THERAPY Increased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin M. Isabel Fiel,
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationEighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus
Chapter 1 Prevention Introduction Eighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Cases of fatty liver and nonalcoholic
More informationReduced telaprevir dosing in combination therapy for patients with chronic hepatitis C
Original Contribution Kitasato Med J 2017; 47: 1-9 Reduced telaprevir dosing in combination therapy for patients with chronic hepatitis C Wataru Ando, 1 Yumi Fukunaga, 1 Hiroaki Yokomori, 2 Takako Komiyama
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationTreatment of chronic hepatitis D patients with pegylated interferon: a real world experience
Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience Zaigham Abbas, Mohammad Sadik Memon, Hammad Mithani, Wasim Jafri, Saeed Hamid Antiviral Therapy 2014; 10.3851/IMP2728
More informationThe Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
Gut and Liver, Published online August 14, 2017 ORiginal Article The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients Shinya Taki 1, Hideyuki Tamai 1, Yoshiyuki Ida 1,
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationHEPATITIS C VIRUS (HCV) IS A BLOOD-BORNE. Laboratory diagnosis of viral hepatitis C The Sultan Qaboos University Hospital experience
SQU JOURNAL FOR SCIENTIFIC RESEARCH: MEDICAL SCIENCES 2003 VOL 5, NO. 1 2, 15 20 SULTAN QABOOS UNIVERSITY Laboratory diagnosis of viral hepatitis C The Sultan Qaboos University Hospital experience *Said
More informationProtection against persistence of hepatitis C
Mechanisms of disease Protection against persistence of hepatitis C Shruti H Mehta, Andrea Cox, Donald R Hoover, Xiao-Hong Wang, Qing Mao, Stuart Ray, Steffanie A Strathdee, David Vlahov, David L Thomas
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More information